Tesamorelin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-11. Anything still debated is marked as such rather than presented as settled.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
=== North Melbourne Football Club (1999) === In 1999, Thompson joined the North Melbourne Football Club as an assistant coach under senior coach Denis Pagan in what became a premiership year for the Kangaroos in the 1999 season, when North Melbourne defeated Carlton in the 1999 Grand Final to win the premiership.
The most widely used route is similar to the cumene process in reaction mechanism and involves the dialkylation of benzene with propene to give 1,4-diisopropylbenzene. This compound reacts with air to afford the bis(hydroperoxide), which is structurally similar to cumene hydroperoxide and rearranges in acid to give acetone and hydroquinone. A second route involves hydroxylation of phenol over a catalyst. The conversion uses hydrogen peroxide and affords a mixture of hydroquinone and its ortho isomer catechol (benzene-1,2-diol): C6H5OH + H2O2 → C6H4(OH)2 + H2O Other, less common methods include:
Diabetic retinopathy, caused by alterations in retinal microcirculation, leading to the growth of friable and poor-quality new blood vessels in the retina or capillary closure which causes ischemia or extravasation of intravascular content, causing edema (swelling of the macula). Retinopathy is the most common cause of blindness among non-elderly adults in the developed world. Diabetic nephropathy, damage to the kidney due to increased glomerular pressure and hyperfiltration can lead to end-stage chronic kidney disease that may require renal dialysis. In most parts of the world, diabetes mellitus is the leading cause of end-stage kidney disease (ESKD). Diabetic nephropathy is increasingly recognized as a significant cause of ESKD in renal allograft recipients. Diabetic neuropathy, Neuropathies in diabetes may cause sensory, mononeuritis, and autonomic neuropathy symptoms, muscle weakness, and potentially life-threatening complications like diabetic foot syndrome (Diabetic amyotrophy) and myocardial infarctions. Intensive insulin therapy is recommended to reduce neuropathy risk, while oral antidiabetic drugs are recommended for pain treatment. Diabetic encephalopathy, Diabetes causes brain functional and structural disturbances, known as diabetic encephalopathy. Various mechanisms are proposed, like alterations to the vascular supply of the brain, or changes in cerebral function and structure, including cognitive impairment, cerebral signal conduction, neurotransmission, and synaptic plasticity are more insidious.
=== Automobile airbags and aircraft evacuation slides === Airbag formulations through late 1990s to early 2000s contained mixtures of oxidizers, sodium azide and other agents including ignitors and accelerants. An electronic controller detonates this mixture during an automobile crash:
Sources: en.wikipedia.org
Brown (1912–2004), American chemist known for work on organoboranes, 1979 Nobel Prize in Chemistry Jeannette Brown (born 1934), American organic medicinal chemist, historian, and author, known for research on drug development targeting tuberculosis and coccidiosis Jeanette Grasselli Brown (1928–2025), American analytical chemist and spectroscopist Rachel Fuller Brown (1898–1980), American chemist who co-developed the first useful antifungal antibiotic, nystatin
=== Physical properties === Adipose tissue has a density of ~0.9 g/ml. Thus, a person with more adipose tissue will float more easily than a person of the same weight with more muscular tissue, since muscular tissue has a density of 1.06 g/ml.
Guzmán G. (1983). The genus Psilocybe: A Systematic Revision of the Known Species Including the History, Distribution and Chemistry of the Hallucinogenic Species. Nova Hedwigia Beihefte. Vol. 74. Berlin: J. Cramer. ISBN 978-3-7682-5474-8. Bresinsky A, Besl H (1989). A Colour Atlas of Poisonous Fungi: a Handbook for Pharmacists, Doctors, and Biologists. London, UK: Manson Publishing Ltd. ISBN 978-0-7234-1576-3. Stamets P. (1996). Psilocybin Mushrooms of the World: An Identification Guide. Berkeley, California: Ten Speed Press. ISBN 978-0-89815-839-7. Gartz J. (1997). Magic Mushrooms Around the World. Los Angeles, California: LIS Publications. ISBN 978-0-9653399-0-2.
Xi and CCP ideologues coined the phrase "Chinese Dream" to describe his overarching plans for China as its leader. Xi first used the phrase during a high-profile visit to the National Museum of China on 29 November 2012, where he and his Politburo Standing Committee colleagues were attending a "national revival" exhibition. Since then, the phrase has become the signature political slogan of the Xi era. The origin of the term "Chinese Dream" is unclear. While the phrase has been used before by journalists and scholars, some publications have posited the term likely drew its inspiration from the concept of the American Dream. The Economist noted the abstract and seemingly accessible nature of the concept with no specific overarching policy stipulations may be a deliberate departure from the jargon-heavy ideologies of his predecessors. Xi has linked the "Chinese Dream" with the phrase "great rejuvenation of the Chinese nation".
Sample acquisition: the most commonly used samples for metagenomic sequencing are blood, stool, cerebrospinal fluid (CSF), urine, or nasopharyngeal swabs. Among these, blood and CSF are the cleanest, having less background noise, while the others are expected to have a great amount of commensals and/or opportunistic infections and thus have more background noise. Samples should be collected with much caution as surgical specimens could be contaminated during handling of the biopsy; for example, lumbar punctures to obtain CSF specimens may be contaminated during the procedure. RNA/DNA extraction: the DNA and the RNA of the sample is extracted by using an extraction kit. If there is a strong previous suspicion of the pathogen genome composition and since the amount of pathogen nucleic acid in more noise samples is overwhelmed by the RNA/DNA of other organisms, selecting an extraction kit of only RNA or DNA would be a more specific and convenient approach. Some commerciable available kits are for example RNeasy PowerSoil Total RNA kit (Qiagen), RNeasy Minikit (Qiagen), MagMAX Viral Isolation kit (ABI), Viral RNA Minikit (Qiagen). Optimization strategies for library preparation: because of high levels of background noise in metagenomic sequencing, several target enrichment procedures have been developed that aim to increase the probability of capturing pathogen-derived transcripts and/or genomes. Generally there are two main approaches that can be used to increase the amount of pathogen signal in a sample: negative selection and positive enrichment.
Sources: en.wikipedia.org
or the coupling reagent COMU which is readily soluble as a dimethylmorpholine-uronium salt and which, like Oxyma, is superior to the standard additive HOBt for the suppression of racemization and acylation efficiency and is comparable to HOAt without presenting an explosion risk such as the benzotriazoles. With water-soluble derivatives of ethyl cyanohydroxyiminoacetate (glyceroacetonide-oxyma) as additive and DIC as coupling reagent even in weakly basic aqueous solutions the linking of protected amino acids to oligopeptides is possible with a yield of 95% and a diastereomeric excess of> 99% using the model substances Z-L-Phg-OH and L-H-Pro-NH2.
==== Concerns ==== Numerous scholars and regulatory bodies have raised concerns over the safety profile of such products. One group of scholars argue that organic solvents introduce compounds into the standardized product that may affect the liver; these compounds are not extracted by water and are consequently largely absent from kava prepared with water. For instance, when compared with water extraction, organic solvents extract vastly larger amounts of flavokavains, compounds associated with adverse reactions to kava that are present in very low concentrations in noble kava, but significant in non-noble. They also point out that chemical solvents and water extract different compounds, and "[t]he extraction process may exclude important modifying constituents soluble only in water". In particular, it has been noted that, unlike traditional water-based preparations, products obtained with the use of organic solvents do not contain glutathione, an important liver-protecting compound. Another group of researchers noted that "the extraction process (aqueous vs. acetone in the two types of preparations) is responsible for the difference in toxicity as extraction of glutathione in addition to the kava lactones is important to provide protection against hepatotoxicity." It has also been argued that kavalactone extracts are often made from low-quality plant material, including the toxic aerial parts of the plant that contain the hepatotoxic alkaloid pipermethystine, non-noble kava varieties, or plants affected by mold.
=== Economics === In December 2019, the US FDA approved a generic version of apixaban produced jointly by Mylan and Micro Labs. BMS and Pfizer worked quickly to block generics from being created, and in August 2020, they won a patent infringement lawsuit against Sigmapharm, Sunshine Lake, and Unichem, after previously settling patent cases against 25 other companies. In September 2021, a Federal Circuit Court upheld the ruling. The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031. In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban. Pfizer reported revenue of US$6.747 billion for Eliquis in 2023. Apixaban is one of ten medications covered by price negotiations in the US under the Inflation Reduction Act. The negotiations, conducted by the Centers for Medicare & Medicaid Services, apply to pricing for Medicare recipients. The results of the negotiations were announced in August 2024, and Medicare's negotiated price for a 30-day supply of Eliquis is $231, a 56% decrease from the 2023 list price of $521. The pricing is set to take effect in 2026.
== Pharmacology == The fenethylline molecule results when theophylline is covalently linked with amphetamine by an alkyl chain. Fenethylline is metabolized by the body to form two drugs, amphetamine (24.5% of oral dose) and theophylline (13.7% of oral dose), both of which are active stimulants. The physiological effects of fenethylline therefore seem to result from a combination of these two compounds, although it is not entirely clear how, and seems to involve a synergistic effect between amphetamine and theophylline produced following metabolism. The pharmacological actions of fenethylline before cleavage also remain poorly established, though it appears to act directly at several serotonin receptors.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.